We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-14.36%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$203M
AUM Growth
-$48.1M
Cap. Flow
-$4.46M
Cap. Flow %
-2.19%
Top 10 Hldgs %
43.02%
Holding
56
New
10
Increased
13
Reduced
12
Closed
7

Top Buys

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$3.87M
2
INDP icon
Indaptus Therapeutics
INDP
+$3.69M
3
XOMA
Xoma
XOMA
+$3.63M
4
BPMC
Blueprint Medicines
BPMC
+$3.6M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$3.28M

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$7.91M
2
MDXG icon
MiMedx Group
MDXG
+$7.15M
3
CMRX
Chimerix, Inc.
CMRX
+$6.42M
4
CEMP
Cempra, Inc.
CEMP
+$4.83M
5
MGNX icon
MacroGenics
MGNX
+$3.42M

Sector Composition

Rank Sector Weight
1 Healthcare 89.51%
2 Miscellaneous 10.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSY
51
DELISTED
Insys Therapeutics, Inc.
INSY
– –
-89,000
Closed -$3.2M
NDRM
52
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
– –
-26,000
Closed -$399K
1 2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2015 Portfolio in Review

As of Q3 2015, Opaleye Management held 56 positions worth $203M, down 19% from $251M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Opaleye Management's Q3 2015 filing shows 10 new, 13 increased, 12 reduced and 7 closed positions. Its largest new stake was TG Therapeutics: 260,000 shares worth $2.62M. The largest sale was Clovis Oncology, Inc., an estimated $7.91M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 94% a quarter earlier, followed by Miscellaneous.

  • Opaleye Management's largest Q3 2015 buy was TG Therapeutics: 260,000 shares worth $2.62M.
  • Opaleye Management added most to Xoma in Q3 2015, an estimated $3.63M increase.
  • Opaleye Management's biggest Q3 2015 reduction was Chimerix, Inc., cutting an estimated $6.42M.
  • Opaleye Management fully exited Clovis Oncology, Inc. in Q3 2015, selling an estimated $7.91M.
  • Opaleye Management's ten largest holdings make up 43% of its $203M portfolio in Q3 2015.
  • Opaleye Management opened 10 new positions and closed 7 in Q3 2015.
  • Opaleye Management's portfolio value fell 19% quarter-over-quarter to $203M.

Based on Opaleye Management's 13F filing for Q3 2015, filed 13 Nov 2015.